Aisling Capital Management LP

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 5, 2026), Aisling Capital Management LP reported 13 stock positions worth $476.3 million. Its top holding was Bridgebio Pharma (BBIO) at 79.4% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 6.5%) and Monte Rosa Therapeutics (GLUE, 5.4%). Compared with Q4 2025, it opened 1 new position, sold out of 1 and added to 3. The biggest buy was Monte Rosa Therapeutics (GLUE, shares +6%) and the biggest sale an exit from Calcimedica (CALC).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0001766721
Portfolio Value
$476.3M (Q1 2026)
SEC Filing
0001766721-26-000002 ↗ filed May 5, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $295.5M Q1 2024 Q2 2024: $231.1M Q2 2024 Q3 2024: $261.1M Q3 2024 Q4 2024: $281.8M Q4 2024 Q1 2025: $288.5M Q1 2025 Q2 2025: $359.7M Q2 2025 Q3 2025: $456.4M Q3 2025 Q4 2025: $478.9M Q4 2025 Q1 2026: $476.3M $476.3M Q1 2026 Q2 2026: $471.6M Q2 2026

Holdings 13 stocks · $476.3M
BBIO Bridgebio Pharma Inc. 79.35% 5,089,611 $378.0M No change
SNDX Syndax Pharmaceuticals Inc. 6.46% 1,316,806 $30.8M No change
GLUE Monte Rosa Therapeutics Inc. 5.37% 1,555,664 $25.6M Add +5.7%
BCAX Bicara Therapeutics Inc. 2.38% 568,919 $11.3M No change
BBOT Bridgebio Oncology Therapeut 1.91% 1,018,018 $9.1M Add +80.3%
CMPS Compass Pathways PLC 1.66% 1,432,336 $7.9M Add +19.5%
SRRK Scholar Rock Holding Corp. 0.80% 77,031 $3.8M No change
BMEA Biomea Fusion Inc. 0.66% 2,048,757 $3.1M No change
EPRX Eupraxia Pharmaceuticals Inc. 0.49% 325,000 $2.4M New
URGN Urogen Pharma Ltd. 0.41% 108,000 $1.9M No change
ACRS Aclaris Therapeutics Inc. 0.34% 434,455 $1.6M No change
MRKR Marker Therapeutics Inc. 0.09% 325,370 $423K No change
OKUR Onkure Therapeutics Inc. Class A 0.08% 88,607 $367K No change

Portfolio Sells Q4 2025 → Q1 2026
CALC Calcimedica Inc. Sold out 0.00% −0.72

Portfolio Buys Q4 2025 → Q1 2026
GLUE Monte Rosa Therapeutics Inc. Add +5.7% 5.37% +0.55
EPRX Eupraxia Pharmaceuticals Inc. New 0.49% +0.49
BBOT Bridgebio Oncology Therapeut Add +80.3% 1.91% +0.44
CMPS Compass Pathways PLC Add +19.5% 1.66% −0.06

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 14$471.6MBBIO, GLUE, SNDX, CMPS, BCAX
Q1 2026 13$476.3MBBIO, SNDX, GLUE, BCAX, BBOT
Q4 2025 13$478.9MBBIO, SNDX, GLUE, BCAX, CMPS
Q3 2025 14$456.4MBBIO, VRNA, SNDX, NUVB, GLUE
Q2 2025 13$359.7MBBIO, VRNA, SNDX, GLUE, BCAX
Q1 2025 13$288.5MBBIO, VRNA, SNDX, BCAX, GLUE
Q4 2024 15$281.8MBBIO, VRNA, SNDX, GLUE, PSTX
Q3 2024 16$261.1MBBIO, VRNA, SNDX, BCAX, BMEA
Q2 2024 15$231.1MBBIO, SNDX, VRNA, ELEV, NUVB
Q1 2024 16$295.5MBBIO, SNDX, VRNA, ELEV, BMEA